Abstract
Introduction Increasing corona virus disease 2019 (COVID-19) pre-test probability can minimize testing patients who are less likely to have COVID-19 and therefore reducing personal protective equipment and COVID-19 testing kit use. The aim of this study was to identify patients who were likely to test positive for COVID-19 among symptomatic patients suspected of having COVID-19 during hospitalization by comparing COVID-19 positive and negative patients.
Method We conducted a retrospective chart review of patients who were ≥18 years old and underwent COVID-19 Polymerase chain reaction test because they presented with symptoms thought to be due to COVID-19. A Poisson regression analysis was conducted after clinical presentation, demographic, medical co-morbidities, laboratory and chest image data was retrieved from the medical records.
Results Charts of 277 and 18 COVID-19 negative and positive patients respectively were analyzed. Dyspnea (61%) was the most common symptom among COVID-19 negative patients, while 72% and 61% COVID-19 positive patients had cough and fever respectively.
COVID-19 positive patients were more likely to present initially with cough [1.082 (1.022 - 1.145)], fever [1.066 (1.014 - 1.121)] and be 50 to 69 years old [1.094 (1.021 - 1.172)]. Dyspnea, weakness, lymphopenia and bilateral chest image abnormality were not associated with COVID-19 positivity.
COVID-19 positive patients were less likely to have non-COVID-19 respiratory viral illness [1.068 (1.019 - 1.119)], human immunodeficiency virus [0.849 (0.765 - 0.943)] and heart failure history [0.093 (0.891 - 0.978)]. Other chronic medical problems (hypertension, diabetes mellitus, chronic obstructive pulmonary disease and coronary artery disease) were not associated with testing positive for COVID-19.
Conclusion Cough, fever and being 50 to 69 years old are better predictors of symptomatic COVID-19 positivity during hospitalization. Despite published studies reporting a high prevalence of lymphopenia among COVID-19 positive patients, lymphopenia is not associated with the risk of testing positive for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Unfunded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PeaceHealth institutional review board (IRB) approved the study and waived the written informed consent requirement. IRB #1591426-3
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
